Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial-Reference-Cited by-同舟云学术

Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial

Published:2018-06 Issue:6 Volume:5 Page:e261-e269
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Shen Qiu-Dan,Zhu Hua-Yuan,Wang Li,Fan Lei,Liang Jin-Hua,Cao Lei,Wu Wei,Xia Yi,Li Jian-Yong,Xu Wei

Funder

National Natural Science Foundation of China

Jiangsu Province's Medical Elite Programme

Project of National Key Clinical Specialty, National Science & Technology Pillar Program

Jiangsu Provincial Special Program of Medical Science

National Science and Technology Major Project

Publisher

Elsevier BV

Subject

Hematology

Reference33 articles.

1. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011;Al-Hamadani;Am J Hematol,2015

2. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification;Sun;Am J Clin Pathol,2012

3. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001;Morton;Blood,2006

4. A predictive model for aggressive non-Hodgkin's lymphoma;N Engl J Med,1993

5. Diffuse large B-cell lymphoma in the elderly: a review of potential difficulties;Sarkozy;Clin Cancer Res,2013

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A prospective phase 2 study of combination epigenetic therapy against relapsed/refractory peripheral T cell lymphoma;Med;2024-07

2. A novel anoikis-related signature predicts prognosis risk and treatment responsiveness in diffuse large B-cell lymphoma;Expert Review of Molecular Diagnostics;2024-05-03

3. Predictors of Survival, Treatment Modalities, and Clinical Outcomes of Diffuse Large B-Cell Lymphoma in Patients Older Than 70 Years Still an Unmet Medical Need in 2024 Based on Real-World Evidence;Cancers;2024-04-11

4. Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group;Annals of Hematology;2024-03-09

5. The management of newly diagnosed large B‐cell lymphoma: A British Society for Haematology Guideline;British Journal of Haematology;2024-01-21